Bruker Corporation (NASDAQ:BRKR) Receives $56.79 Consensus Target Price from Brokerages

Bruker Corporation (NASDAQ:BRKR) has earned an average rating of “Hold” from the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $56.7857.

BRKR has been the topic of several research analyst reports. Stifel Nicolaus set a $45.00 target price on shares of Bruker in a research note on Friday, May 8th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Wolfe Research began coverage on shares of Bruker in a research report on Monday, June 1st. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. raised their target price on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Finally, Citigroup lifted their price objective on Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th.

Bruker Stock Up 4.2%

BRKR stock opened at $64.34 on Friday. Bruker has a 1-year low of $28.53 and a 1-year high of $64.54. The business has a fifty day moving average price of $57.81 and a 200-day moving average price of $46.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The stock has a market capitalization of $9.79 billion, a P/E ratio of -268.08, a P/E/G ratio of 1.98 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. During the same period in the prior year, the company posted $0.47 earnings per share. The company’s quarterly revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts forecast that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Monday, June 22nd. Bruker’s dividend payout ratio is -83.33%.

Institutional Investors Weigh In On Bruker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC purchased a new stake in shares of Bruker in the fourth quarter worth $26,000. Allworth Financial LP increased its holdings in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the last quarter. Essential Partners LLC purchased a new stake in shares of Bruker during the 1st quarter worth approximately $36,000. Parallel Advisors LLC raised its stake in Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in shares of Bruker in the 4th quarter valued at about $50,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.